Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief

This article was originally published in The Tan Sheet

Executive Summary

Valeant acquires iNova, closes Afexa deal; CRN says FDA’s proposed rule on gifts “goes too far”; Kentucky bill would strengthen PSE limits; and more OTC drug and nutritional product market news In Brief

You may also be interested in...



Supplement Industry Critics On Agenda For FDA's Ingredient List Meeting

FDAs Oct. 3 meeting agenda includes Pieter Cohen, Harvard Medical School professor; Consumers Union Programs Director Chuck Bell; Laura MacCleery, Center for Science in the Public Interest regulatory affairs director; and Stephanie Scarmo, Pew Charitable Trusts Health Care Products Project officer.

Prestige Brands Shows International Ambition In Care Pharmaceuticals Buy

The acquisition of Australian OTC firm Care Pharmaceuticals brings Prestige Brands a portfolio of pediatric and women’s health products, as well as potential entrée into additional Asia Pacific markets.

Prestige Brands Shows International Ambition In Care Pharmaceuticals Buy

The acquisition of Australian OTC firm Care Pharmaceuticals brings Prestige Brands a portfolio of pediatric and women’s health products, as well as potential entrée into additional Asia Pacific markets.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS105437

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel